Current Hypertension Reports

, 16:413

Innate Immunity in Hypertension

  • Muhammad Oneeb Rehman Mian
  • Pierre Paradis
  • Ernesto L. Schiffrin
Hypertension and Metabolic Syndrome (J Sowers and A Whaley-Connell, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Hypertension and Metabolic Syndrome

Abstract

Despite intensive research, the exact cause of hypertension remains unknown. Low-grade inflammation has been proposed to play a key role in the pathogenesis of hypertension. Both innate and adaptive immune responses may participate in this process. Several studies have addressed the contribution of adaptive immunity to the pathophysiology of high blood pressure; however, the role of innate immunity is less clear. Innate immunity may be an important mediator of chronic inflammation in hypertension. Slight elevation of blood pressure due to increased sympathetic and/or decreased parasympathetic outflow, or low-grade infections may generate neoantigens and damage-activated molecular patterns (DAMPs) or pathogen-activated molecular patterns (PAMPs), which can trigger Toll-like receptors on innate effector cells. Innate responses, mediated by monocytes, macrophages, dendritic cells and natural killer cells, may contribute to inflammation either directly or by activating adaptive immune responses mediated by T lymphocytes. In this review, we discuss the recent evidence regarding the contribution of different innate effector cells, their response and their mechanisms of activation in hypertension.

Keywords

Blood pressure Inflammation Innate immunity Toll-like receptors DAMPs Target organ damage 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Leibowitz A, Schiffrin EL. Immune mechanisms in hypertension. Curr Hypertens Rep. 2011;13:465–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension. 2012;59:367–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Tian N, Moore RS, Braddy S, et al. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol. 2007;293:H3388–95.PubMedCrossRefGoogle Scholar
  5. 5.•
    Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29:543–8. This review discusses the role of T effector and regulatory lymphocytes in blood pressure regulation.PubMedCrossRefGoogle Scholar
  6. 6.
    Barhoumi T, Kasal DA, Li MW, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469–76.PubMedCrossRefGoogle Scholar
  7. 7.
    Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59:324–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Franco M, Martinez F, Quiroz Y, et al. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol. 2007;293:R251–6.PubMedCrossRefGoogle Scholar
  9. 9.
    De Ciuceis C, Amiri F, Brassard P, et al. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol. 2005;25:2106–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Ko EA, Amiri F, Pandey NR, et al. Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am J Physiol Heart Circ Physiol. 2007;292:H1789–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Leibovitz E, Ebrahimian T, Paradis P, et al. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009;27:2192–200.PubMedCrossRefGoogle Scholar
  12. 12.••
    Javeshghani D, Barhoumi T, Idris-Khodja N, et al. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension. 2013;62:112–7. This study shows that macrophages play a role in endothelin-1-induced vascular injury.PubMedCrossRefGoogle Scholar
  13. 13.••
    Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation. 2011;124:1370–81. This study elegantly demonstrates a role for circulating monocytes and infiltrating macrophages in angiotensin II-induced hypertension by selective ablation of lysozyme M-positive (LysM + ) myelomonocytic cells by low-dose diphtheria toxin in mice with inducible expression of the diphtheria toxin receptor (LysM iDTR mice).PubMedCrossRefGoogle Scholar
  14. 14.•
    Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci. 2014;126:267–74. Review of the role of immune mechanisms in vascular injury in hypertension with an in-depth description of the mechanisms of action of T regulatory lymphocytes.PubMedCrossRefGoogle Scholar
  15. 15.
    Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res. 2004;94:1203–10.PubMedCrossRefGoogle Scholar
  16. 16.
    Elmarakby AA, Quigley JE, Olearczyk JJ, et al. Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension. 2007;50:1069–76.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Liao TD, Yang XP, Liu YH, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 2008;52:256–63.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.•
    Kossmann S, Schwenk M, Hausding M, et al. Angiotensin II-induced vascular dysfunction depends on interferon-gamma-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arterioscler Thromb Vasc Biol. 2013;33:1313–9. This study demonstrates that NK cells, in cooperation with monocytes, produce IFN-γ, which is important for angiotensin II-induced vascular damage.PubMedCrossRefGoogle Scholar
  19. 19.
    Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075–81.PubMedCrossRefGoogle Scholar
  20. 20.
    Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004;44:248–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Kriska T, Cepura C, Magier D, et al. Mice lacking macrophage 12/15-lipoxygenase are resistant to experimental hypertension. Am J Physiol Heart Circ Physiol. 2012;302:H2428–38.PubMedCrossRefGoogle Scholar
  23. 23.•
    Machnik A, Neuhofer W, Jantsch J, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009;15:545–52. In this and the following study (ref. [24]••), the authors demonstrated a role for skin macrophages in the regulation of salt and water retention, and therefore blood pressure regulation.PubMedCrossRefGoogle Scholar
  24. 24.••
    Machnik A, Dahlmann A, Kopp C, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension. 2010;55:755–61. See above, ref. [23]•.Google Scholar
  25. 25.
    Yamamoto S, Yancey PG, Zuo Y, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:2856–64.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Investig. 2010;120:3350–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity. 2011;35:323–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010;10:236–47.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336–47.PubMedCrossRefGoogle Scholar
  30. 30.•
    Vinh A, Chen W, Blinder Y, et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122:2529–37. The authors demonstrated that costimulation of T cells via B7 is critical for the development of hypertension in response to angiotensin II.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132–40.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Taherzadeh Z, VanBavel E, de Vos J, et al. Strain-dependent susceptibility for hypertension in mice resides in the natural killer gene complex. Am J Physiol Heart Circ Physiol. 2010;298:H1273–82.PubMedCrossRefGoogle Scholar
  33. 33.
    de Vries MR, Seghers L, van Bergen J, et al. C57BL/6 NK cell gene complex is crucially involved in vascular remodeling. J Mol Cell Cardiol. 2013;64C:51–8.CrossRefGoogle Scholar
  34. 34.
    Jin C, Henao-Mejia J, Flavell RA. Innate immune receptors: key regulators of metabolic disease progression. Cell Metab. 2013;17:873–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511.PubMedCrossRefGoogle Scholar
  36. 36.
    Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007;4:444–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Bomfim GF, Dos Santos RA, Oliveira MA, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci. 2012;122:535–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Wallin RP, Lundqvist A, More SH, et al. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 2002;23:130–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Pockley AG, Wu R, Lemne C, et al. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension. 2000;36:303–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Pons H, Ferrebuz A, Quiroz Y, et al. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am J Physiol Ren Physiol. 2013;304:F289–99.CrossRefGoogle Scholar
  41. 41.
    Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA : J Am Med Assoc. 2008;300:924–32.CrossRefGoogle Scholar
  42. 42.
    Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Davey Smith G, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25:1051–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Miller YI, Chang MK, Binder CJ, et al. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003;14:437–45.PubMedCrossRefGoogle Scholar
  45. 45.
    Taguchi A, Sanada M, Suei Y, et al. Tooth loss is associated with an increased risk of hypertension in postmenopausal women. Hypertension. 2004;43:1297–300.PubMedCrossRefGoogle Scholar
  46. 46.
    Tonetti MS, D’Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356:911–20.PubMedCrossRefGoogle Scholar
  47. 47.•
    Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension. 2012;59:755–62. This is a brief but good review on autonomic neural regulation of the immune system in hypertension and cardiovascular disease with an emphasis on the anti-inflammatory role of the parasympathetic system.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Elenkov IJ, Wilder RL, Chrousos GP, et al. The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595–638.PubMedGoogle Scholar
  49. 49.
    Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335–46.PubMedCrossRefGoogle Scholar
  50. 50.
    Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.PubMedCrossRefGoogle Scholar
  51. 51.
    Grebe KM, Takeda K, Hickman HD, et al. Cutting edge: sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis. J Immunol. 2010;184:540–4.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Grisanti LA, Woster AP, Dahlman J, et al. Alpha1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. J Pharmacol Exp Ther. 2011;338:648–57.PubMedCrossRefGoogle Scholar
  53. 53.
    Harwani SC, Chapleau MW, Legge KL, et al. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res. 2012;111:1190–7.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.•
    Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in hypertension. Front Physiol. 2012;3:128. This review comprehensively discusses the recent data on the roles of innate and adaptive immunity in hypertension.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500–7.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Pietrowski E, Bender B, Huppert J, et al. Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H– oxidase derived reactive oxygen species. J Vasc Res. 2011;48:52–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Lee DL, Leite R, Fleming C, et al. Hypertensive response to acute stress is attenuated in interleukin-6 knockout mice. Hypertension. 2004;44:259–63.PubMedCrossRefGoogle Scholar
  58. 58.
    Brands MW, Banes-Berceli AK, Inscho EW, et al. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension. 2010;56:879–84.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Zhang W, Wang W, Yu H, et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension. 2012;59:136–44.PubMedCrossRefGoogle Scholar
  60. 60.
    Shao J, Nangaku M, Miyata T, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension. 2003;42:31–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Viel EC, Lemarie CA, Benkirane K, et al. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol. 2010;298:H938–44.PubMedCrossRefGoogle Scholar
  62. 62.
    Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–32.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Sales ML, Schreiber R, Ferreira-Sae MC, et al. The functional Toll-like receptor 4 Asp299Gly polymorphism is associated with lower left ventricular mass in hypertensive women. Clin Chim Acta Int J Clin Chem. 2010;411:744–8.CrossRefGoogle Scholar
  65. 65.
    Sales ML, Schreiber R, Ferreira-Sae MC, et al. Toll-like receptor 6 Ser249Pro polymorphism is associated with lower left ventricular wall thickness and inflammatory response in hypertensive women. Am J Hypertens. 2010;23:649–54.PubMedCrossRefGoogle Scholar
  66. 66.
    Marketou ME, Kontaraki JE, Zacharis EA, et al. TLR2 and TLR4 gene expression in peripheral monocytes in nondiabetic hypertensive patients: the effect of intensive blood pressure-lowering. J Clin Hypertens. 2012;14:330–5.CrossRefGoogle Scholar
  67. 67.
    Marketou ME, Kontaraki JE, Tsakountakis NA, et al. Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am J Cardiol. 2011;107:59–63.PubMedCrossRefGoogle Scholar
  68. 68.
    Imakiire T, Kikuchi Y, Yamada M, et al. Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. Hypertens Res : Off J Japan Soc Hypertens. 2007;30:635–42.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Muhammad Oneeb Rehman Mian
    • 1
  • Pierre Paradis
    • 1
  • Ernesto L. Schiffrin
    • 1
    • 2
  1. 1.Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General HospitalMcGill UniversityMontrealCanada
  2. 2.Department of Medicine, Sir Mortimer B. Davis-Jewish General HospitalMcGill UniversityMontrealCanada

Personalised recommendations